Recall, Withdrawal and Corrective Actions for Medical Devices in Belarus
Updated: 2026-11-12 · GRZAN Regulatory Team · Verification date 2026-10-20
1. Key takeaways
The withdrawal from circulation, return to the producer, or destruction of medical devices in Belarus is not a commercial decision that a company takes at its own discretion; it is a statutory procedure executed in accordance with the regulation approved by Resolution No. 177. Procedural compliance matters as much as the physical outcome of the disposal. A manufacturer that removes products from the market quickly but skips the required notifications, records or witnessed disposal steps has not, in the eyes of the regulator, completed a compliant disposal — it has merely created the appearance of one. Because Resolution No. 378 has now transferred the related quality and safety inspection and counterfeit database functions to the supervisory institution, the enforcement side of this procedure has become more concentrated, and the practical standard for demonstrating that a disposal was lawful has risen accordingly. This article walks through the three dispositions, the procedural prerequisites, the link to the adverse event line, and the Union-level mechanisms that apply when an event crosses borders.
2. Legal basis
| Instrument | Number / registration | Adoption / entry into force | Provision |
|---|---|---|---|
| Resolution on Certain Issues of Medical Device Circulation | Council of Ministers No. 177 (5/52905) | In force 2024-03-17 | Article 1 approves the Procedures and Conditions for Withdrawal from Circulation, Return to the Producer, or Destruction |
| Healthcare Law | No. 2435-XII | 1993-06-18 | Article 39-1, paragraphs 9 and 13 |
| Resolution on Amending Several Resolutions of the Council of Ministers | Council of Ministers No. 378 (6-2/56159) | In force 2026-07-30 | Amends No. 177; transfers quality and safety inspection and counterfeit database functions |
| EEC Board Decision on the Monitoring Rules | No. 174 | 2015-12-22 | Union-level correction and withdrawal mechanisms |
3. Expert insights
Insight 1: withdrawal from circulation has three possible destinations, and destruction is only one of them. The title of the regulation itself lists three dispositions: withdrawal from circulation, return to the producer, and destruction. When drafting a disposal plan, manufacturers should first determine which disposition applies to the facts at hand instead of defaulting to destruction. In a number of situations, returning the product to the producer is both feasible and less costly — it preserves value, simplifies logistics for cross-border stock, and may avoid the administrative burden of organizing witnessed destruction. The choice, however, must be made against the conditions in the regulation, not against commercial convenience alone, and the reasoning behind the choice should be documented in the disposal file.
Insight 2: the prerequisite for disposal is compliance with the procedures and conditions. The regulation governs not only whether a product may be withdrawn, but how it must be done — the scope of notification, the record-keeping requirements, the witnessing of the disposal and similar elements. A company that completes only the physical removal of stock from the market, without performing the procedural steps, may still be found to have disposed of the product in a non-compliant manner. In practice this means that notification lists, disposal records and witness arrangements should be planned at the same time as the field logistics, and the disposal file should be closed only when the procedural evidence set is complete.
Insight 3: the disposal procedure is connected in series with the adverse event procedure. The detection and analysis of adverse events — the first regulation approved by Resolution No. 177 — typically triggers the disposal decision under the second regulation. In practice the two lines form a single chain: detection, then analysis, then the disposal decision, then execution of the disposal, then archiving of the records. Manufacturers who manage the two regulations as separate silos tend to lose the traceability link between the triggering event and the disposal action, which is exactly the link an inspector will ask them to reconstruct.
Insight 4: Union-level suspension and withdrawal mechanisms also exist. At the Union level there are provisions for suspending use, prohibiting use and withdrawing products from circulation; the number of the relevant decision has not been verified by GRZAN and is treated as pending verification. Disposal decisions for events that span several member states must therefore take into account both the national procedure and the Union mechanisms, and the two must be coordinated rather than run in parallel without reference to each other. A disposal executed only under national procedure may not, by itself, satisfy the Union-side expectations in a multi-country event.
4. Practical recommendations
- Determine the destination before executing a disposal plan. Among withdrawal, return and destruction, make an applicability judgment against the conditions in the regulation first, document the reasoning, and only then execute the chosen disposition.
- Give procedural compliance the same weight as physical disposal. Complete notification, record-keeping and witnessing in step with the removal action, and treat the three as gates that must be passed before the disposal file is closed.
- Build a closed-loop ledger from detection to archiving. Maintain a ledger in which every disposal batch can be traced back to the triggering event and forward to the execution and archive records, so the chain can be reconstructed on demand.
- Assess Union mechanisms for cross-member-state events. Do not cover a multi-country scenario with the national procedure alone; check the Union-level suspension and withdrawal provisions for each affected member state.
5. Verification checklist
- □ The disposal plan has determined whether withdrawal, return or destruction applies
- □ Notification, record-keeping and witnessing have been completed in step with the removal action
- □ A closed-loop ledger from detection through disposal to archiving has been established
- □ Union mechanisms have been assessed together with the national procedure for cross-member-state events
- □ The procedure has been executed under No. 177 as amended by No. 378
Regulatory information verified as of 30 October 2026.
In the Eurasian Economic Union market, GRZAN concentrates its core capabilities on three fronts. First, distinguishing the applicable conditions and the remaining time windows of the two channels — Union-level unified registration and national registration in each member state. The national registration procedure of Belarus has been fully restructured by Council of Ministers Resolution No. 211 of 28 April 2026 (state registration number 6-1/55925, in force 1 May 2026): the total time limit for preliminary technical work is compressed to 90 calendar days, the scope list is closed and implementing organizations are prohibited from expanding it, while the window for filing applications under the national procedure takes 31 December 2027 as the key milestone, so path selection must be decided in step with the time window. Second, local authorized representative services: GRZAN acts as the statutory representative of the manufacturer in Belarus, handling registration filings, responses to technical queries, changes to the registration dossier and post-market reporting obligations, and it has already synchronized its liaison mechanisms after Council of Ministers Resolution No. 378 of 27 July 2026 (in force 30 July 2026) transferred adverse event functions to the State Institution for State Pharmaceutical Supervision (Gosfarmnadzor). Third, quality system and testing support: GRZAN helps establish a quality management system conforming to ISO 13485 and organizes technical documentation according to the target path — the national path follows the annex to Ministry of Health Resolution No. 55, while the Union path follows Eurasian Economic Commission Council Decision No. 46. For post-market compliance in the Belarusian market — vigilance, recalls and responses to supervisory inspections — GRZAN provides end-to-end support built on the same framework.
Business enquiries: info@grzanglobal.com
Disclaimer
Prepared by GRZAN from publicly available regulation. It is provided for general information only and does not constitute legal advice. Legislation and official fees are subject to change by the competent authority.
About GRZAN
GRZAN (Global Regulatory Zone Access Navigator) — the global market-access navigator for medical devices and IVDs.
GRZAN is a specialist consultancy for medical device and IVD market access, providing end-to-end regulatory solutions across the product lifecycle and making international market entry simpler and faster.
Key figures. More than 25 wholly owned subsidiaries worldwide covering 50+ countries and regions; chosen by 100+ listed and leading Chinese device manufacturers, with 4,000+ successful cases; 12+ years in the sector and 200+ regulatory training sessions and seminars delivered.
What we do. Global market access: multi-country registration programmes, technical documentation, regulatory advice. Clinical evidence: clinical evaluation reports (CER), usability studies, overseas clinical investigations. Quality systems: ISO 13485, MDSAP, FDA QMSR and BGMP implementation and audit readiness. Authorised representative and licence-holder services across Southeast Asia, Latin America, the Middle East, Africa, Europe and North America.
Why GRZAN. A real operating entity, with the certificate held by the manufacturer: our direct overseas subsidiaries act as the compliant local holder, so the regulatory relationship stays clear and you keep control rather than being tied to a distributor. Direct access to the team: no time-zone gap, no language barrier, no cultural gap. Review points anticipated: we know what FDA 510(k), EU MDR, Southeast Asian, Latin American and Middle Eastern reviewers look for, which shortens timelines and reduces deficiency letters. Pathway planning: pre-decision analysis and risk assessment before you commit.
Every engagement rests on three commitments: efficiency through pre-submission review, certainty through a clear pathway, and stability through a licence-holder that stays in place.
Take your devices global with GRZAN
We work with manufacturers worldwide to open new markets with a clear regulatory pathway.
Contact us